Omnicell, Inc. (OMCL)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Omnicell, Inc. (OMCL) trades at $32.75 with AI Score 50/100 (Hold). Omnicell, Inc. provides medication management solutions and adherence tools for healthcare systems and pharmacies. Market cap: $1.49B, Sector: Healthcare.
Last analyzed: Feb 8, 2026Omnicell, Inc. (OMCL) Healthcare & Pipeline Overview
Omnicell, Inc. revolutionizes medication management with automated solutions for healthcare systems and pharmacies, enhancing safety, efficiency, and adherence, positioning them as a key player in optimizing medication workflows and patient outcomes with a market capitalization of $1.70 billion.
Investment Thesis
Omnicell presents a notable research candidate due to its position in the growing healthcare automation market. The company's comprehensive suite of medication management solutions addresses critical needs for efficiency, safety, and adherence in healthcare systems. With a market capitalization of $1.70 billion and a gross margin of 42.5%, Omnicell demonstrates financial stability. Growth catalysts include the increasing adoption of automation in pharmacies and hospitals, driven by labor shortages and the need to reduce medication errors. The company's EnlivenHealth Patient Engagement platform offers further growth potential by improving patient adherence and outcomes. The company's P/E ratio is high at 812.20, but this may reflect high growth expectations. Successful execution of its growth strategies and continued innovation in medication management will drive long-term value for investors.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $1.70 billion, reflecting a substantial presence in the healthcare technology market.
- Gross margin of 42.5%, indicating strong pricing power and efficient cost management.
- P/E ratio of 812.20, suggesting high investor expectations for future earnings growth.
- Beta of 0.77, indicating lower volatility compared to the overall market.
- Profit Margin of 0.2% indicates the company has opportunity to improve profitability.
Competitors & Peers
Strengths
- Comprehensive product portfolio in medication management.
- Established customer base in hospitals and pharmacies.
- Strong focus on innovation and technology.
- Recurring revenue from maintenance and support contracts.
Weaknesses
- High P/E ratio may indicate overvaluation.
- Profit margin of 0.2% indicates opportunity to improve profitability.
- Dependence on capital spending by hospitals and pharmacies.
- Competition from larger and more diversified healthcare companies.
Catalysts
- Ongoing: Increasing demand for automation in pharmacies and hospitals.
- Ongoing: Expansion of the EnlivenHealth Patient Engagement platform.
- Upcoming: Potential acquisitions of complementary businesses.
- Ongoing: Integration of solutions with leading EHR systems.
- Ongoing: Development of new medication management technologies.
Risks
- Potential: Economic downturn may reduce capital spending by healthcare providers.
- Potential: Technological obsolescence of existing products.
- Ongoing: Increased competition from new entrants.
- Potential: Regulatory changes affecting medication management practices.
- Potential: Integration challenges with hospital information systems.
Growth Opportunities
- Expanding the EnlivenHealth Patient Engagement Platform: The market for patient engagement solutions is growing rapidly as healthcare providers seek to improve patient adherence and outcomes. Omnicell can expand its EnlivenHealth platform by adding new features and integrations, targeting a larger share of this market. Timeline: Ongoing, with continuous updates and new features planned for the next 3-5 years. This will help drive revenue growth and improve patient satisfaction.
- Increasing Adoption of Automation in Pharmacies: The increasing demand for automation in pharmacies, driven by labor shortages and the need to reduce medication errors, presents a significant growth opportunity for Omnicell. The company can expand its market share by offering comprehensive automation solutions tailored to the needs of different pharmacy settings. Timeline: 2-3 years, with a focus on expanding sales and marketing efforts.
- Geographic Expansion: Omnicell has the opportunity to expand its geographic reach by targeting new markets outside the United States. The demand for medication management solutions is growing globally, particularly in emerging markets with rapidly developing healthcare systems. Timeline: 3-5 years, with a focus on establishing partnerships and distribution channels in new regions.
- Strategic Acquisitions: Omnicell can pursue strategic acquisitions to expand its product portfolio and market presence. Acquiring companies with complementary technologies or customer bases can accelerate growth and create synergies. Timeline: Ongoing, with a focus on identifying and evaluating potential acquisition targets. This will allow the company to offer a more comprehensive suite of solutions and reach new customers.
- Integration with Electronic Health Records (EHRs): The integration of Omnicell's solutions with EHRs can improve data flow and workflow efficiency for healthcare providers. This integration can enhance the value proposition of Omnicell's products and drive adoption. Timeline: 1-2 years, with a focus on developing and implementing integration solutions with leading EHR vendors. This will improve data accuracy and reduce manual data entry.
Opportunities
- Increasing adoption of automation in healthcare.
- Expansion into new geographic markets.
- Strategic acquisitions to expand product portfolio.
- Integration with electronic health records (EHRs).
Threats
- Economic downturn may reduce capital spending by healthcare providers.
- Technological obsolescence of existing products.
- Increased competition from new entrants.
- Regulatory changes affecting medication management practices.
Competitive Advantages
- Proprietary technology in medication management and automation.
- Established relationships with hospitals and pharmacies.
- Comprehensive product portfolio covering various aspects of medication management.
- High switching costs for customers due to integration with existing systems.
About OMCL
Omnicell, Inc., founded in 1992 and headquartered in Mountain View, California, has evolved into a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies worldwide. Originally named Omnicell Technologies, Inc., the company rebranded in 2001 to reflect its expanding focus on comprehensive medication management. Omnicell's core offerings include point-of-care automation solutions designed to streamline clinician workflows in patient care areas. Their XT Series automated dispensing systems manage medications and supplies in nursing units and operating rooms. The company also provides central pharmacy automation solutions, including XR2 Automated Central Pharmacy System, IV compounding robots, and inventory management software. These systems automate storage, retrieval, and compounding processes, improving efficiency and accuracy. Omnicell's single-dose automation solutions cater to institutional pharmacies, offering automated packaging of medications to enhance adherence in non-acute care settings. Their EnlivenHealth Patient Engagement platform further supports patient adherence through web-based solutions. With a global presence, Omnicell continues to innovate in medication management, addressing the evolving needs of healthcare providers and patients.
What They Do
- Provides automated dispensing systems for medications and supplies.
- Offers central pharmacy automation solutions, including storage and retrieval systems.
- Develops IV compounding robots and workflow management systems.
- Provides inventory management software for pharmacies.
- Offers controlled substance management systems.
- Provides single-dose automation solutions for medication packaging.
- Offers a web-based patient engagement platform.
Business Model
- Sells automated medication dispensing and management systems.
- Provides software and services for pharmacy automation.
- Generates revenue through recurring maintenance and support contracts.
- Offers patient engagement solutions on a subscription basis.
Industry Context
Omnicell operates in the healthcare information services industry, which is experiencing significant growth due to the increasing adoption of technology in healthcare. The market for pharmacy automation is expected to grow as hospitals and pharmacies seek to improve efficiency, reduce errors, and manage costs. Omnicell competes with companies offering similar automation solutions, as well as traditional medication management methods. The company's comprehensive product portfolio and focus on innovation position it well to capitalize on the growth opportunities in this market. Key trends include the integration of automation with electronic health records (EHRs) and the increasing use of data analytics to optimize medication management.
Key Customers
- Hospitals and healthcare systems
- Retail pharmacies
- Long-term care facilities
- Government healthcare providers
Financials
Chart & Info
Omnicell, Inc. (OMCL) stock price: $32.75 (+0.26, +0.74%)
Latest News
-
3 Cash-Heavy Stocks with Warning Signs
Yahoo! Finance: OMCL News · Mar 24, 2026
-
Should You Continue to Hold OMCL Stock in Your Portfolio?
zacks.com · Mar 24, 2026
-
Financial Analysis: Omnicell (NASDAQ:OMCL) versus Nyxoah (NASDAQ:NYXH)
defenseworld.net · Mar 22, 2026
-
How The Titan XT Cycle Is Rewriting The Omnicell (OMCL) Investment Story
Yahoo! Finance: OMCL News · Mar 5, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OMCL.
Price Targets
Consensus target: $53.50
MoonshotScore
What does this score mean?
The MoonshotScore rates OMCL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
3 Cash-Heavy Stocks with Warning Signs
Should You Continue to Hold OMCL Stock in Your Portfolio?
Financial Analysis: Omnicell (NASDAQ:OMCL) versus Nyxoah (NASDAQ:NYXH)
How The Titan XT Cycle Is Rewriting The Omnicell (OMCL) Investment Story
Latest Omnicell, Inc. Analysis
What Investors Ask About Omnicell, Inc. (OMCL)
What does Omnicell, Inc. do?
Omnicell, Inc. is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. The company offers a comprehensive suite of products and services, including automated dispensing systems, central pharmacy automation solutions, IV compounding robots, inventory management software, and patient engagement platforms. Omnicell's solutions help healthcare providers improve efficiency, reduce medication errors, and enhance patient safety. The company's EnlivenHealth Patient Engagement platform further supports patient adherence and outcomes, making Omnicell a key player in optimizing medication workflows and patient care.
Is OMCL stock worth researching?
OMCL stock presents a mixed investment picture. On the positive side, the company operates in a growing market for healthcare automation and has a comprehensive product portfolio. However, the high P/E ratio of 812.20 suggests that the stock may be overvalued. Investors may want to evaluate the company's growth prospects, competitive landscape, and valuation before making a decision. Successful execution of its growth strategies and continued innovation in medication management will be critical for driving long-term value. The company's beta of 0.77 suggests it is less volatile than the market.
What are the main risks for OMCL?
The main risks for OMCL include the potential for an economic downturn to reduce capital spending by healthcare providers, technological obsolescence of existing products, increased competition from new entrants, and regulatory changes affecting medication management practices. Additionally, integration challenges with hospital information systems could hinder adoption of Omnicell's solutions. Investors should carefully consider these risks before investing in OMCL. The company's ability to adapt to changing market conditions and maintain its competitive advantage will be crucial for its long-term success.
What are the key factors to evaluate for OMCL?
Omnicell, Inc. (OMCL) currently holds an AI score of 50/100, indicating moderate score. The stock trades at a P/E of 765.5x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Analysts target $53.50 (+63% from $32.75). Key strength: Comprehensive product portfolio in medication management.. Primary risk to monitor: Potential: Economic downturn may reduce capital spending by healthcare providers.. This is not financial advice.
How frequently does OMCL data refresh on this page?
OMCL prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven OMCL's recent stock price performance?
Recent price movement in Omnicell, Inc. (OMCL) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $53.50 implies 63% upside from here. Notable catalyst: Comprehensive product portfolio in medication management.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider OMCL overvalued or undervalued right now?
Determining whether Omnicell, Inc. (OMCL) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 765.5. Analysts target $53.50 (+63% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying OMCL?
Before investing in Omnicell, Inc. (OMCL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.